Improvements to tiny body-on-a-chip devices could lead to next-generation pre-clinical testing of drug toxicity
Researchers at Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) in Japan have designed a small ‘body-on-a-chip’ device that can test the side effects of drugs s on human cells. The device solves some issues with current, similar microfluidic devices and offers promise for the next generation of pre-clinical drug tests.
The Integrated Heart/Cancer on a Chip (iHCC) was used to test the toxicity of the anti-cancer drug doxorubicin on heart cells. The researchers, led by iCeMS’s Ken-ichiro Kamei, found that, while the drug itself was not toxic to heart cells, a metabolite of the drug resulting from its interaction with cancer cells was.
The device is smaller than a microscope glass slide. It contains six tiny chambers; every two are connected by microchannels with a series of port inlets and valves. A pneumatic pump controls movement of fluid through the channels. Every two chambers and their separate microchannel system constitute one test bed. Three test beds in the device allow for the introduction of minor changes in each bed to simultaneously compare results.
The team first tested doxorubicin’s effects on heart cells and liver cancer cells cultured separately in small wells. The drug had the expected anti-cancer effect on the cancer cells without causing damage to the heart cells.
They then ran the test using the iHCC device. Heart cells were placed in one chamber while liver cancer cells were placed in the other. Doxorubicin was introduced into a cell culture medium circulating through a closed-loop system of microchannels that connects the two chambers, mimicking the blood’s circulatory system. In this way, the drug flows unidirectionally in a continuous loop through both chambers.
The team found signs of toxicity in both cancer and heart cells. They hypothesized that a compound, doxorubicinol, which is a metabolic byproduct of doxorubicin interacting with cancer cells, was causing the toxic effect.
To test this, they added doxorubicinol to heart cells and liver cancer cells cultured separately in small wells. It was toxic to the heart cells but not to the cancer cells.
When doxorubicin alone is added to the liver cancer cells, the amount of doxorubicinol produced is too small to be toxic to the heart cells. The team believes this is because the amount of cell culture medium needed for the well-based tests dilutes the metabolite.
In contrast, when doxorubicin is introduced into the iHCC, the metabolite is not diluted when moving through the microchannel circulation system because a smaller volume of cell culture is needed. As a result, the drug does have a toxic effect on the heart cells via its metabolite.
The device requires further improvements, but the study demonstrates how this design concept could be used to investigate the toxic side effects of anti-cancer drugs on heart cells well before expensive clinical trials. The study was published in the journal Royal Society of Chemistry Advances.
Learn more:Â Next-generation drug testing on chips
The Latest on:Â Body-on-a-chip
[google_news title=”” keyword=”body-on-a-chip” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Top 5 blue-chip companies with upside potentialon March 28, 2024 at 12:13 am
These stocks, commonly known as blue chips, have weathered previous storms and remain resilient ... oils also hit the stock as palm oil is a key raw material for HUL’s body washes and a few food ...
- Revolutionizing Wireless Communication: How Tiny Chips Could Transform Medical Technologyon March 26, 2024 at 8:04 am
This innovative method furthers the development of wireless sensor technology and opens the door to the potential use of vast numbers of unobtrusive sensors in implantable and wearable biomedical ...
- A Beating Heart on a Chipon March 26, 2024 at 7:12 am
T he simple, constant rhythm of a beating heart is a reassuring sign of life. With each lub-dub, blood brings life-sustaining oxygen throughout the body. But behind this steady beat is a busy ...
- Organ-on-a-chip technology revolutionizes drug development for women's healthon March 25, 2024 at 5:00 pm
Instead of using electronic circuits to promote fluid flow, the mini-organs obtain their nutrients via channels no wider than a human hair that transport fluids into the chips. The microchips can thus ...
- Wall Street Breakfast Podcast: China Blocks Intel, AMD Chips In Government Computerson March 25, 2024 at 3:50 am
China said to block use of Intel, AMD chips in government computers. Boeing union wants board seat to 'save company from itself' - report. Germany cannabis legalization on schedule.
- SOXX: Gain Broader AI Exposure, Amid Chip Recoveryon March 24, 2024 at 11:58 pm
The semiconductor industry recovery bodes well for iShares Semiconductor ETF. Learn more about SOXX and why it seems better than SMH for 2024.
- 6 weird things that happen to your body at high altitudeon March 23, 2024 at 8:08 am
Some odd things happen to your body at higher elevations, some of which we can explain and some of which we can’t ...
- New alveolar soft-part sarcoma chip can mimic the microenvironment during angiogenesison March 22, 2024 at 7:23 am
Cancer, the second leading cause of death worldwide, is more likely to respond to effective treatment if identified early before metastasizing, resulting in a greater probability of surviving.
- Why giving AI a robot body could make its ‘brain’ more human-likeon March 21, 2024 at 2:30 pm
At its AI conference, Nvidia announced new software and hardware for AI-powered humanoid robots: a model called Project GR00T and a computer called Jetson Thor ...
- Watch Neuralink’s first human brain-chip patient play chess via thoughton March 20, 2024 at 8:15 pm
Neuralink has live streamed a video showing its first human patient using its brain implant to play chess just by thinking about it.
via Google News and Bing News